Coating process: production process of alkyd resin modified emulsion paint
The breakthrough anticancer drug of Albright has been accepted by CDE
First line treatment of NSCLC with cindilimab reached the main end point
The proportion of medical insurance funds will increase the development space of innovative pharmaceutical enterprises
The R & D investment of 8.7 million yuan, Tonghua Dongbao xigliptin metformin tablets (Ⅱ) registration application accepted
China's diabetes drugs may be in short supply by 2030
The R & D investment is 16 million yuan, lasting for 7 years, and the new drug shagliptin tablet of aosaikang pharmaceutical industry is approved to go on the market
The results showed that azacytidine combined with nafumab showed good response rate and overall survival rate in the treatment of AML
Diabetes market scale will continue to grow and antidiabetic drugs will be upgraded soon
Nat Genet: scientists develop new methods of cancer precision medicine, which can give drugs one-on-one with precision
"Zero tariff of anticancer drugs" is expected to be broken
Long-term use of metformin in high-risk diabetic patients is not related to cognitive decline
Strategy integration of pharmaceutical enterprises under the new normal of the industry
The new compound diabetes drug o'shuangning (R) was approved in China
More than 400 million patients in the world! Ten breakthroughs in 2016 "help" conquer diabetes
Elkem's US $1.695 billion acquisition of tobira to strengthen gastroenterology pipeline
J & J's $1.1 billion acquisition of three anti HCV pipelines to beat Gillette and Aberdeen
Johnson & Johnson makes efforts in the field of hepatitis C: $1.1 billion to buy three new anti hepatitis drugs under research
AstraZeneca became four strategic cooperation in immunooncology
Hepatitis C drug harvoni of Gilead is licensed for marketing in Europe